Kura Oncology (KURA) Prices 8.11M Share Common Offering at $37/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Kura Oncology (KURA) to Offer $200M in Common Stock
December 7, 2020 4:01 PM ESTKura Oncology, Inc. (Nasdaq: KURA) announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell $200,000,000 of shares of its common stock. In connection with the offering, Kura expects to grant the underwriters a 30-day option to... More
Pre-Open Stock Movers 12/07: (KODK) (CKH) Higher; (RIDE) (XPEV) (JKS) Lower (more...)
December 7, 2020 9:26 AM ESTToday's Pre-Open Stock Movers
Eastman Kodak Company (NYSE: KODK) 72% HIGHER; news that federal regulators found no wrongdoing in getting a loan from the government.
Kura Oncology, Inc. (Nasdaq: KURA) 16.9% HIGHER; announced preliminary clinical data from KOMET-001, an ongoing Phase 1/2A clinical trial of the Companys oral, potent and selective menin inhibitor, KO-539, including single-agent activity in genetically defined subgroups of patients with relapsed or refractory acute myeloid leukemia (AML).
Matinas BioPharma Holdings, Inc. (NYSE:... More
Kura Oncology (KURA) PT Raised to $45 at H.C. Wainwright After ASH Presentation
December 7, 2020 7:12 AM ESTH.C. Wainwright analyst Joseph Pantginis raised the price target on Kura Oncology (NASDAQ: KURA) to $45.00 (from $40.00) after an oral presentation at ASH offered the first important look at preliminary Phase 1/2a data with KO-539 in r/r AML patients from the ongoing KOMET... More
Kura Oncology (KURA) PT Raised to $47 at Barclays
December 7, 2020 4:47 AM ESTBarclays analyst Peter Lawson raised the price target on Kura Oncology (NASDAQ: KURA) to $47.00 (from $40.00) while maintaining a Overweight rating.... More
